Pregled bibliografske jedinice broj: 1000956
Monitoring of specific immunotherapy in children allergic to hymenoptera venom by improved venom by improved basophil activation test
Monitoring of specific immunotherapy in children allergic to hymenoptera venom by improved venom by improved basophil activation test // 33rd Congress of the International Society for Advancement of Cytometry
Prag, Češka Republika, 2018. (poster, međunarodna recenzija, ostalo, stručni)
CROSBI ID: 1000956 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Monitoring of specific immunotherapy in children allergic to hymenoptera venom by improved venom by improved basophil activation test
(Monitoring of specific immunotherapy in children allergic to hymenoptera venom by improved basophil activation test)
Autori
Živković, J., Zenić, L., Bulat Lokas, S., Nogalo, B., Turkalj, M., Polančec, D.
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, ostalo, stručni
Skup
33rd Congress of the International Society for Advancement of Cytometry
Mjesto i datum
Prag, Češka Republika, 28.04.2018. - 02.05.2018
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
SIT, BAT, Allergic reaction
Sažetak
Introduction: The most effective way of preventing severe allergic reactions caused by hymenoptera venom is specific immunotherapy (SIT). Although serum specific IgE and skin prick test are most often used diagnostic methods in allergies, they do not provide a real predictive value after immunotherapy, especially when the test is performed a year after the last allergic reaction. Basophil activation test (BAT) is used as a functional test to monitor basophil activation upon in vitro allergen challenge by detecting the expression of membrane surface markers. Although different studies have shown that CD63 is the most promising basophil activation and degranulation marker, we decided to used it in combination with CD203c, which allowed us to separately monitor basophil activation and degranulation. Methods: Peripheral blood samples of children allergic to hymenoptera venom were prepared using the FlowCAST® (Bühlmann, Switzerland) CCR3/CD63 staining protocol, with the addition of the antibodies against CD45 and CD203c. Blood was drawn before starting SIT and one year after the first treatment. Log dilutions of hymenoptera venom allergen ranging from 10μg/ml to 10 pg/ml final concentration were made. Acquisition of the samples was performed using the Navios flow cytometer (Beckman Coulter, USA) and the data were analysed using the FlowLogic™ software (Inivai Technologies, Australia). The percentage of activated basophils and the mean fluorescence intensity (MFI) for all markers was determined. Results: There was an up-regulation of CD203c among samples treated with different allergen concentrations even when there was no up- regulation of CD63, i.e. the differences in CD203c expression were observed during non-degranulating stimulation of basophils. Also, there was a simultaneous decrease in CD63 and CD203c expression one year after SIT, indicating a development of tolerance to hymenoptera venom. Conclusion: The use of CD203c, together with CD45 and CD63/CCR3 improves sensitivity of BAT and enables determination of the activated/non- degranulated and activated/degranulated basophils. This kind of an improved BAT has become important in diagnosis of allergy to insect venom at our hospital, allowing us to distinguish between allergic and sensitized patients with additional benefit in monitoring of SIT. Our results imply that BAT might impose a promising diagnostic tool for predicting the outcome of immunotherapy, allowing a better optimization of the treatment and reduction of the potential harmful
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Dječja bolnica Srebrnjak,
Fakultet za dentalnu medicinu i zdravstvo, Osijek